Divergent mechanisms of action of the inflammatory cytokines interleukin 1-β and tumour necrosis factor-α in mouse cremasteric venules

被引:28
作者
Young, RE [1 ]
Thompson, RD [1 ]
Nourshargh, S [1 ]
机构
[1] Univ London Imperial Coll Sci & Technol, Hammersmith Hosp, Natl Heart & Lung Inst, BHF Cardiovasc Med Unit,Fac Med, London W12 0NN, England
关键词
cytokine; inflammation; intravital microscopy; leukocyte; chemoattractant;
D O I
10.1038/sj.bjp.0704981
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Protein synthesis dependency and the role of endogenously generated platelet activating factor (PAF) and leukotriene B-4 (LTB4) in leukocyte migration through interleukin-1beta (IL-1beta)- and tumour necrosis factor-alpha (TNFalpha)-stimulated mouse cremasteric venules was investigated using established pharmacological interventions and the technique of intravital microscopy. 2 Based on previously obtained dose-response data, 30 ng rmIL-1beta and 300 ng rmTNFalpha were injected intrascrotally (4 h test period) to induce comparable levels of leukocyte firm adhesion and transmigration in mouse cremasteric venules. 3 Co-injection of the mRNA synthesis inhibitor, actinomycin D (0.2 mg kg(-1)), with the cytokines significantly inhibited firm adhesion (49+/-13.6%) and transmigration (67.2+/-4.2%) induced by IL-1beta, but not TNFalpha. 4 In vitro, TNFalpha (1-100 ng ml(-1)), but not IL-1beta, stimulated L-selectin shedding and increased beta(2) integrin expression on mouse neutrophils, as quantified by flow cytometry. 5 The PAF receptor antagonist, UK-74,505 (modipafant, 0.5 mg kg(-1), i.v.), had no effect on adhesion induced by either cytokine, but significantly inhibited transmigration induced by IL-1beta (66.5+/-4.5%). 6 The LTB4 receptor antagonist, CP-105,696 (100 mg kg(-1), p.o.), significantly inhibited both IL-1beta induced adhesion (81.4+/-15.2%) and transmigration (58.7+/-7.2%), but had no effect on responses elicited by TNFa. Combined administration of the two antagonists had no enhanced inhibitory effects on responses induced by either cytokine. 7 The data indicate that firm adhesion and transmigration in mouse cremasteric venules stimulated by IL-1beta, but not TNFa, is protein synthesis dependent and mediated by endogenous generation of PAF and LTB4. Additionally, TNFalpha but not IL-1beta, can directly stimulate mouse neutrophils in vitro. The findings provide further evidence to suggest divergent mechanisms of actions of IL-1beta and TNFalpha, two cytokines often considered to act via common molecular/cellular pathways.
引用
收藏
页码:1237 / 1246
页数:10
相关论文
共 64 条
[1]  
ALABASTER VA, 1991, AGENT ACTION SUPPL, V34, P221
[2]   Role of NO and PAF in the impairment of skeletal muscle contractility induced by TNF-α [J].
Alloatti, G ;
Penna, C ;
Mariano, F ;
Camussi, G .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2000, 279 (06) :R2156-R2163
[3]  
Barnes PJ, 1998, PHARMACOL REV, V50, P515
[4]   IDENTIFICATION OF AN INDUCIBLE ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE [J].
BEVILACQUA, MP ;
POBER, JS ;
MENDRICK, DL ;
COTRAN, RS ;
GIMBRONE, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (24) :9238-9242
[5]   ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE-1 - AN INDUCIBLE RECEPTOR FOR NEUTROPHILS RELATED TO COMPLEMENT REGULATORY PROTEINS AND LECTINS [J].
BEVILACQUA, MP ;
STENGELIN, S ;
GIMBRONE, MA ;
SEED, B .
SCIENCE, 1989, 243 (4895) :1160-1165
[6]   ADHESION OF HUMAN BASOPHILS, EOSINOPHILS, AND NEUTROPHILS TO INTERLEUKIN 1-ACTIVATED HUMAN VASCULAR ENDOTHELIAL-CELLS - CONTRIBUTIONS OF ENDOTHELIAL-CELL ADHESION MOLECULES [J].
BOCHNER, BS ;
LUSCINSKAS, FW ;
GIMBRONE, MA ;
NEWMAN, W ;
STERBINSKY, SA ;
DERSEANTHONY, CP ;
KLUNK, D ;
SCHLEIMER, RP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (06) :1553-1556
[7]   RECOMBINANT INTERLEUKIN-1-BETA INTERACTS WITH HIGH-AFFINITY RECEPTORS TO ACTIVATE NEUTROPHIL LEUKOTRIENE-B4 SYNTHESIS [J].
BORISH, L ;
ROSENBAUM, R ;
MCDONALD, B ;
ROSENWASSER, LJ .
INFLAMMATION, 1990, 14 (02) :151-162
[8]   LEUKOTRIENES AND INFLAMMATION [J].
BRAIN, SD ;
WILLIAMS, TJ .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (01) :57-66
[9]  
BRANDT E, 1992, J IMMUNOL, V149, P1356
[10]  
BRENNAN FM, 1992, BRIT J RHEUMATOL, V31, P293